Submission of Unaudited standalone & Consolidated financial results for the quarter ended 30.06.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medi-Caps Limited posted weak Q1 FY26 results with zero standalone revenue from operations (down from ₹89.08 lakhs a year ago), as the company has not generated any revenue from real estate operations during the quarter. Standalone net loss stood at ₹39.75 lakhs versus a profit of ₹70.61 lakhs in Q1 FY25, with EPS turning negative at -₹0.32. On a consolidated basis, revenue from operations fell sharply to ₹268.76 lakhs from ₹619.44 lakhs YoY (~57% decline), driven entirely by the Pharma division (subsidiary Medgel Pvt Ltd). The consolidated net loss widened significantly to ₹349.19 lakhs from a loss of ₹55.65 lakhs in the year-ago quarter, with the Pharma segment alone reporting a loss of ₹308.14 lakhs. Total comprehensive income was -₹196.75 lakhs on a consolidated basis.
Shareholders should note the sharp deterioration in profitability, with both standalone and consolidated results swinging from profit to loss, and the pharma subsidiary dragging group-level earnings deeply into the red. The absence of real estate revenue and continued losses at the pharma subsidiary raise concerns about near-term earnings recovery and could pressure the stock negatively.